Wiezorek Jeffrey 4
4 · Kite Pharma, Inc. · Filed Sep 27, 2017
Insider Transaction Report
Form 4
Wiezorek Jeffrey
VP Clinical Development
Transactions
- Award
Common Stock
2017-09-25+10,000→ 31,107 total - Sale
Common Stock
2017-09-25$179.66/sh−5,283$949,164→ 25,824 total
Footnotes (2)
- [F1]Includes 36 shares acquired under the 2014 Employee Stock Purchase Plan on August 18, 2017.
- [F2]The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.